Recent 8-K filings for CORT
Highest-materiality recent filing
Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly
- 30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.
- Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).
-
Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved
Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.
-
FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer
Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
-
Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B
Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).
-
Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents
Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.
-
Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction
Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).
-
FDA issues Complete Response Letter for Corcept's relacorilant NDA in hypercortisolism
FDA concluded benefit-risk assessment unfavorable without additional effectiveness evidence.
-
Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M
Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.
-
FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026
FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.
-
Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M
Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.
-
Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer
NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.
-
Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.
-
30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.
-
FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025
FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).
-
Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M
Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).
-
Corcept submits NDA for relacorilant to treat Cushing's syndrome
NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.
-
Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results
Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.
-
Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M
Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.
-
Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M
Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.78 · Most common event earnings